Kyle Moran's most recent trade in Wave Life Sciences Ltd. was a trade of 252,000 Share Option (right to buy) done . Disclosure was reported to the exchange on Feb. 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 252,000 | 252,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 42,000 | 89,218 (0%) | 0% | 0 | Ordinary Shares | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 25,000 | 0 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 11 Oct 2024 | 25,000 | 44,777 (0%) | 0% | 2.5 | 62,000 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 25 Sep 2024 | 17,146 | 19,777 (0%) | 0% | 9 | 154,314 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.17 per share. | 03 Apr 2024 | 15,630 | 33,921 (0%) | 0% | 6.2 | 96,421 | Ordinary Shares |
| Wave Life Sciences Ltd. | Moran Kyle | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2024 | 371,500 | 371,500 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 23 Aug 2023 | 37,062 | 46,120 (0%) | 0% | 4.8 | 176,119 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 272,700 | 272,700 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 16 Feb 2023 | 9,729 | 79,751 (0%) | 0% | 4.0 | 39,305 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2022 | 60,000 | 60,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 15,000 | 89,588 (0%) | 0% | 0 | Ordinary Shares | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 04 May 2022 | 5,021 | 84,567 (0%) | 0% | 1.7 | 8,636 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.31 per share. | 16 Feb 2022 | 9,204 | 74,588 (0%) | 0% | 2.3 | 21,261 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 175,000 | 175,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 24 Mar 2021 | 10,930 | 80,792 (0%) | 0% | 2.5 | 27,106 | Ordinary Shares |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2021 | 10,930 | 25,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 71,584 (0%) | 0% | 0 | Ordinary Shares | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 50,000 | 50,000 | - | - | Share Option (right to buy) | |
| Wave Life Sciences Ltd. | Kyle Moran | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.57 per share. | 01 Feb 2021 | 1,722 | 69,862 (0%) | 0% | 10.6 | 18,202 | Ordinary Shares |